fundamentals and the market relationships. You have to put your foot in the water and take some risk or you're not going to make squat. Favorites...AMGN, CELG, BMRN, BIIB,
CMS aka Medicare to continue paying full price for part B drugs; the planned changes affect doctor and hospital reimbursement by reducing it from 6% to 2.5% plus $16.80 flat fee. the biotech companies that sold off today are being punished for no reason. I expect them to recover and move higher. AMGN is well positioned. further catalyst are repatha sales which are going strong ( the company had to hire extra 200+ people to help with the significant demand for this drug).
They are dumb like foxes. They want your money - and they are perfectly willing to lie, cheat and steal to get it.
liberals are the stupidist people on earth! imagine putting that idiot who couldnt fulfill her last job into the most important job. they are dumb people, really dumb.
After watching the GOP debacle, it is hard to believe that these 2 idiots are the best the dems can produce. So sad for the party of lies and socialism.
That would not explain why REGN is down also. Has to do with proposed changes to Medicare Part B being proposed by CMS. It could effect reimbursement rates for some biotech drugs, including Amgen's.
get use to it.......bear market coming........I holding tight.........if it goes too low, Ill buy more
actually i take that back $155 is the 200 sma. shouldn't take too much to get there. maybe a good drug trial. i read they are working on 9 biosimilars.
This is not amgn specific. this is a bear attack on biotech. checkout BIIB, GILD, IBB, BIB, XLV, ^BTK, etc. ETF's and big co's all getting slammed. Hopefully this is the bottom and won't have to test Sept. lows in which case another $10 drop to $130. Someone wants these share cheaper. Maybe ahead of window dressing for 2nd Q who knows.
Right no imho. Sounds like its being manipulated after recent great earnings. Good pipeline and 30 billion in cash. Who cares if a few hedge funds drop out? Ackmen one of the best is down 20% this and last year. I would add at this current level and BTW Clinton will lose to Trump imo.
Sentiment: Strong Buy
joint venture with novartis
he companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule
Novartis and Amgen also plan to co-develop and co-commercialize Amgen's migraine portfolio, including fully human monoclonal antibody AMG 334 with first phase III data expected in 2017
Partnership reinforces Novartis' continued commitment to developing and bringing innovative neuroscience treatment options to patients
Amgen will present at the Cowen and Company 36th Annual Health Care Conference at 9:20 a.m. ET on Tuesday, March 8, 2016, in Boston. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen ( AMGN), will present at the conference